ETF Foundry
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.
reversal factor · long-only model fund

Foundry Long-Term Reversal Factor ETF

ETF Foundry Research (hypothetical) · rebalanced monthly

FLRRHYPOTHETICAL MODEL
Since ’99
−85%
Expense Ratio
0.29%
placeholder
Holdings
257
cap-weighted
Inception
Jul 2020
placeholder
Full Sharpe
-0.32
Ann. Return (LS)
-6.2%
Ann. Volatility
19.3%
Max Drawdown
-86.2%
Test Sharpe ’19–26
-0.55
Test FF5 α (ann.)
-12.0%
vs Fama-French 5
Test FF5 α t-stat
-2.45
significant (|t| ≥ 2)
Monthly turnover
19%
of the long leg, per rebalance
Cumulative return (LS)
-85%
over 283 months
This fund holds the long leg only
Long leg Sharpe
0.41
what this fund holds
Long leg ann. return
9.5%
buyable, long-only
Long-short Sharpe
-0.32
requires shorting
Bottom bucket ann. return
15.7%
the basket shorted

Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.

Hypothetical growth of $1 — long-short backtest

Gross of the placeholder expense ratio and trading costs · not investor results

283 months

Holdings

Every constituent of the long leg — sort, search or filter by sector

257 of 257 · 100.0% of book
TickerCompanySectorMarket capWeight
1EL
ESTEE LAUDER COMPANIES INCConsumer Defensive$29.71B
6.30%
2ILMN
ILLUMINA INCHealthcare$28.24B
5.99%
3ZM
ZOOM COMMUNICATIONS INCTechnology$26.72B
5.66%
4MRNA
MODERNA INCHealthcare$24.53B
5.20%
5ROKU
ROKU INCCommunication Services$21.32B
4.52%
6U
UNITY SOFTWARE INCTechnology$12.66B
2.68%
7W
WAYFAIR INCConsumer Cyclical$11.79B
2.50%
8ARWR
ARROWHEAD PHARMACEUTICALS INCHealthcare$10.47B
2.22%
9DOCU
DOCUSIGN INCTechnology$10.07B
2.13%
10MTCH
MATCH GROUP INCCommunication Services$9.13B
1.94%
11WULF
TERAWULF INCFinancial Services$9.00B
1.91%
12PRAX
PRAXIS PRECISION MEDICINES INCHealthcare$8.77B
1.86%
13SYRE
SPYRE THERAPEUTICS INCHealthcare$8.70B
1.84%
14IBRX
IMMUNITYBIO INCHealthcare$8.04B
1.70%
15VFC
V F CORPConsumer Cyclical$6.65B
1.41%
16PATH
UIPATH INCTechnology$6.30B
1.33%
17ERAS
ERASCA INCHealthcare$5.96B
1.26%
18DNTH
DIANTHUS THERAPEUTICS INCHealthcare$5.77B
1.22%
19TXG
10X GENOMICS INCHealthcare$5.55B
1.18%
20ENPH
ENPHASE ENERGY INCTechnology$5.48B
1.16%
21DFTX
DEFINIUM THERAPEUTICS INCHealthcare$4.83B
1.02%
22LFST
LIFESTANCE HEALTH GROUP INCHealthcare$4.49B
0.95%
23BILL
BILL HOLDINGS INCTechnology$4.45B
0.94%
24RLAY
RELAY THERAPEUTICS INCHealthcare$3.81B
0.81%
25CALY
CALLAWAY GOLF COConsumer Cyclical$3.48B
0.74%
26RNG
RINGCENTRAL INCTechnology$3.46B
0.73%
27RCUS
ARCUS BIOSCIENCES INCHealthcare$3.44B
0.73%
28SEDG
SOLAREDGE TECHNOLOGIES INCTechnology$3.25B
0.69%
29FSLY
FASTLY INCTechnology$3.24B
0.69%
30ONDS
ONDAS INCTechnology$3.23B
0.69%
31AAP
ADVANCE AUTO PARTS INCConsumer Cyclical$3.19B
0.68%
32AXTI
AXT INCTechnology$3.00B
0.64%
33LCID
LUCID GROUP INCConsumer Cyclical$2.87B
0.61%
34BEAM
BEAM THERAPEUTICS INCHealthcare$2.83B
0.60%
35RUN
SUNRUN INCTechnology$2.83B
0.60%
36XRAY
DENTSPLY SIRONA INCHealthcare$2.81B
0.60%
37PENN
PENN ENTERTAINMENT INCConsumer Cyclical$2.75B
0.58%
38KOD
KODIAK SCIENCES INCHealthcare$2.67B
0.57%
39ATAI
ATAIBECKLEY INCHealthcare$2.66B
0.56%
40PTON
PELOTON INTERACTIVE INCConsumer Cyclical$2.55B
0.54%
41SLS
SELLAS LIFE SCIENCES GROUP INCHealthcare$2.45B
0.52%
42NKTR
NEKTAR THERAPEUTICSHealthcare$2.31B
0.49%
43BAND
BANDWIDTH INCTechnology$2.30B
0.49%
44PVLA
PALVELLA THERAPEUTICS INCHealthcare$2.26B
0.48%
45NEOG
NEOGEN CORPHealthcare$2.24B
0.47%
46IOVA
IOVANCE BIOTHERAPEUTICS INCHealthcare$2.23B
0.47%
47NWL
NEWELL BRANDS INCConsumer Defensive$2.22B
0.47%
48AGL
AGILON HEALTH INCHealthcare$2.17B
0.46%
49OMCL
OMNICELL INCHealthcare$2.09B
0.44%
50GLUE
MONTE ROSA THERAPEUTICS INCHealthcare$2.07B
0.44%
51CDNA
CAREDX INCHealthcare$2.05B
0.44%
52NUVB
NUVATION BIO INCHealthcare$2.03B
0.43%
53ZD
ZIFF DAVIS INCCommunication Services$1.99B
0.42%
54ABCL
ABCELLERA BIOLOGICS INCHealthcare$1.97B
0.42%
55KSS
KOHLS CORPConsumer Cyclical$1.96B
0.42%
56FIVN
FIVE9 INCTechnology$1.96B
0.42%
57DMRA
DAMORA THERAPEUTICS INCHealthcare$1.94B
0.41%
58APPN
APPIAN CORPTechnology$1.92B
0.41%
59NEO
NEOGENOMICS INCHealthcare$1.90B
0.40%
60WGS
GENEDX HOLDINGS CORPHealthcare$1.88B
0.40%
61MRVI
MARAVAI LIFESCIENCES HOLDINGS INCHealthcare$1.87B
0.40%
62MQ
MARQETA INCTechnology$1.85B
0.39%
63NVCR
NOVOCURE LTDHealthcare$1.84B
0.39%
64SRPT
SAREPTA THERAPEUTICS INCHealthcare$1.82B
0.39%
65ASAN
ASANA INCTechnology$1.77B
0.38%
66HYMC
HYCROFT MINING HOLDING CORPBasic Materials$1.74B
0.37%
67BFLY
BUTTERFLY NETWORK INCHealthcare$1.73B
0.37%
68SHLS
SHOALS TECHNOLOGIES GROUP INCTechnology$1.73B
0.37%
69FIGS
FIGS INCConsumer Cyclical$1.72B
0.37%
70TSHA
TAYSHA GENE THERAPIES INCHealthcare$1.71B
0.36%
71TDOC
TELADOC HEALTH INCHealthcare$1.70B
0.36%
72CMPS
COMPASS PATHWAYS PLCHealthcare$1.67B
0.35%
73TE
T1 ENERGY INCIndustrials$1.63B
0.35%
74VIR
VIR BIOTECHNOLOGY INCHealthcare$1.59B
0.34%
75NTLA
INTELLIA THERAPEUTICS INCHealthcare$1.59B
0.34%
76INNV
INNOVAGE HOLDING CORPHealthcare$1.56B
0.33%
77LEG
LEGGETT & PLATT INCConsumer Cyclical$1.50B
0.32%
78IART
INTEGRA LIFESCIENCES HOLDINGS CORPHealthcare$1.50B
0.32%
79ULCC
FRONTIER GROUP HOLDINGS INCIndustrials$1.43B
0.30%
80AMN
AMN HEALTHCARE SERVICES INCHealthcare$1.36B
0.29%
81NVAX
NOVAVAX INCHealthcare$1.35B
0.29%
82BW
BABCOCK & WILCOX ENTERPRISES INCIndustrials$1.35B
0.29%
83GPRE
GREEN PLAINS INCBasic Materials$1.35B
0.29%
84LZ
LEGALZOOMCOM INCIndustrials$1.33B
0.28%
85STAA
STAAR SURGICAL COHealthcare$1.32B
0.28%
86XNCR
XENCOR INCHealthcare$1.30B
0.27%
87ABSI
ABSCI CORPHealthcare$1.29B
0.27%
88FCEL
FUELCELL ENERGY INCIndustrials$1.25B
0.27%
89HLF
HERBALIFE LTDConsumer Defensive$1.24B
0.26%
90SAFE
SAFEHOLD INCReal Estate$1.22B
0.26%
91AMRC
AMERESCO INCIndustrials$1.22B
0.26%
92QDEL
QUIDELORTHO CORPHealthcare$1.19B
0.25%
93TNDM
TANDEM DIABETES CARE INCHealthcare$1.17B
0.25%
94XIFR
XPLR INFRASTRUCTURE LPUtilities$1.13B
0.24%
95UPWK
UPWORK INCIndustrials$1.12B
0.24%
96FUBO
FUBOTV INCCommunication Services$1.05B
0.22%
97JBIO
JADE BIOSCIENCES INCHealthcare$1.03B
0.22%
98AVTX
AVALO THERAPEUTICS INCHealthcare$1.02B
0.22%
99APPS
DIGITAL TURBINE INCTechnology$1.01B
0.21%
100OLMA
OLEMA PHARMACEUTICALS INCHealthcare$1.00B
0.21%
101FBRX
FORTE BIOSCIENCES INCHealthcare$1.00B
0.21%
102VOR
VOR BIOPHARMA INCHealthcare$980M
0.21%
103ANNX
ANNEXON INCHealthcare$950M
0.20%
104COUR
COURSERA INCConsumer Defensive$941M
0.20%
105SLDB
SOLID BIOSCIENCES INCHealthcare$859M
0.18%
106HPP
HUDSON PACIFIC PROPERTIES INCReal Estate$853M
0.18%
107CYRX
CRYOPORT INCIndustrials$832M
0.18%
108BKSY
BLACKSKY TECHNOLOGY INCTechnology$823M
0.17%
109RPD
RAPID7 INCTechnology$815M
0.17%
110RJET
REPUBLIC AIRWAYS HOLDINGS INCIndustrials$806M
0.17%
111FOXF
FOX FACTORY HOLDING CORPConsumer Cyclical$798M
0.17%
112ACRS
ACLARIS THERAPEUTICS INCHealthcare$793M
0.17%
113DSGN
DESIGN THERAPEUTICS INCHealthcare$785M
0.17%
114HIPO
HIPPO HOLDINGS INCFinancial Services$764M
0.16%
115GDOT
GREEN DOT CORPFinancial Services$760M
0.16%
116OMER
OMEROS CORPHealthcare$701M
0.15%
117SWIM
LATHAM GROUP INCBasic Materials$692M
0.15%
118BALY
BALLY'S CORPConsumer Cyclical$688M
0.15%
119HELE
HELEN OF TROY LTDConsumer Defensive$655M
0.14%
120TCMD
TACTILE SYSTEMS TECHNOLOGY INCHealthcare$648M
0.14%
121TREE
LENDINGTREE INCFinancial Services$645M
0.14%
122TECX
TECTONIC THERAPEUTIC INCHealthcare$615M
0.13%
123ILPT
INDUSTRIAL LOGISTICS PROPERTIES TRUSTReal Estate$591M
0.13%
124NGNE
NEUROGENE INCHealthcare$590M
0.12%
125MYGN
MYRIAD GENETICS INCHealthcare$584M
0.12%
126PACK
RANPAK HOLDINGS CORPConsumer Cyclical$583M
0.12%
127STTK
SHATTUCK LABS INCHealthcare$577M
0.12%
128FDMT
4D MOLECULAR THERAPEUTICS INCHealthcare$575M
0.12%
129FLGT
FULGENT GENETICS INCHealthcare$573M
0.12%
130RLMD
RELMADA THERAPEUTICS INCHealthcare$550M
0.12%
131XMAX
XMAX INCConsumer Cyclical$541M
0.11%
132TOI
ONCOLOGY INSTITUTE INCHealthcare$535M
0.11%
133MEI
METHODE ELECTRONICS INCTechnology$532M
0.11%
134VSTM
VERASTEM INCHealthcare$530M
0.11%
135CTEV
CLARITEV CORPHealthcare$518M
0.11%
136SPT
SPROUT SOCIAL INCTechnology$518M
0.11%
137ZURA
ZURA BIO LTDHealthcare$518M
0.11%
138ARVN
ARVINAS INCHealthcare$517M
0.11%
139DNA
GINKGO BIOWORKS HOLDINGS INCHealthcare$517M
0.11%
140RGNX
REGENXBIO INCHealthcare$511M
0.11%
141ADV
ADVANTAGE SOLUTIONS INCCommunication Services$508M
0.11%
142SPIR
SPIRE GLOBAL INCIndustrials$488M
0.10%
143MAGN
MAGNERA CORPBasic Materials$487M
0.10%
144AMCX
AMC GLOBAL MEDIA INCCommunication Services$461M
0.10%
145PRTA
PROTHENA CORP PUBLIC LTD COHealthcare$453M
0.10%
146ALTO
ALTO INGREDIENTS INCBasic Materials$453M
0.10%
147MATV
MATIV HOLDINGS INCBasic Materials$442M
0.09%
148BETR
BETTER HOME & FINANCE HOLDING COFinancial Services$442M
0.09%
149BNTC
BENITEC BIOPHARMA INCHealthcare$439M
0.09%
150BNED
BARNES & NOBLE EDUCATION INCConsumer Cyclical$437M
0.09%
151ASPN
ASPEN AEROGELS INCBasic Materials$425M
0.09%
152TENX
TENAX THERAPEUTICS INCHealthcare$420M
0.09%
153QMCO
QUANTUM CORPTechnology$419M
0.09%
154CBIO
CRESCENT BIOPHARMA INCHealthcare$407M
0.09%
155ENTA
ENANTA PHARMACEUTICALS INCHealthcare$400M
0.08%
156ABEO
ABEONA THERAPEUTICS INCHealthcare$399M
0.08%
157EBS
EMERGENT BIOSOLUTIONS INCHealthcare$394M
0.08%
158STRO
SUTRO BIOPHARMA INCHealthcare$391M
0.08%
159CRNC
CERENCE INCTechnology$390M
0.08%
160ABTC
AMERICAN BITCOIN CORPFinancial Services$386M
0.08%
161BBBY
BED BATH & BEYOND INCConsumer Cyclical$372M
0.08%
162ZNTL
ZENTALIS PHARMACEUTICALS INCHealthcare$364M
0.08%
163FNKO
FUNKO INCConsumer Cyclical$326M
0.07%
164BKKT
BAKKT INCTechnology$323M
0.07%
165VELO
VELO3D INCTechnology$316M
0.07%
166MKTW
MARKETWISE INCTechnology$314M
0.07%
167LYEL
LYELL IMMUNOPHARMA INCHealthcare$311M
0.07%
168OFLX
OMEGA FLEX INCIndustrials$302M
0.06%
169TKNO
ALPHA TEKNOVA INCHealthcare$291M
0.06%
170DBI
DESIGNER BRANDS INCConsumer Cyclical$290M
0.06%
171JACK
JACK IN THE BOX INCConsumer Cyclical$286M
0.06%
172MASS
908 DEVICES INCHealthcare$278M
0.06%
173SGHT
SIGHT SCIENCES INCHealthcare$274M
0.06%
174SSTK
SHUTTERSTOCK INCCommunication Services$272M
0.06%
175ZSQR
Z SQUARED INCHealthcare$260M
0.06%
176TBI
TRUEBLUE INCIndustrials$258M
0.05%
177QTTB
Q32 BIO INCHealthcare$255M
0.05%
178SRZN
SURROZEN INCHealthcare$255M
0.05%
179NUS
NU SKIN ENTERPRISES INCConsumer Defensive$254M
0.05%
180RILY
BRC GROUP HOLDINGS INCFinancial Services$254M
0.05%
181ANGI
ANGI INCCommunication Services$248M
0.05%
182RNAC
CARTESIAN THERAPEUTICS INCHealthcare$243M
0.05%
183GLSI
GREENWICH LIFESCIENCES INCHealthcare$240M
0.05%
184RMAX
RE/MAX HOLDINGS INCReal Estate$236M
0.05%
185RDNW
RIDENOW GROUP INCConsumer Cyclical$229M
0.05%
186UP
WHEELS UP EXPERIENCE INCIndustrials$229M
0.05%
187CABO
CABLE ONE INCCommunication Services$223M
0.05%
188KPTI
KARYOPHARM THERAPEUTICS INCHealthcare$216M
0.05%
189SENS
SENSEONICS HOLDINGS INCHealthcare$214M
0.05%
190AGEN
AGENUS INCHealthcare$209M
0.04%
191IMUX
IMMUNIC INCHealthcare$207M
0.04%
192BDSX
BIODESIX INCHealthcare$204M
0.04%
193FOCL
FOCAL INCHealthcare$204M
0.04%
194DTIL
PRECISION BIOSCIENCES INCHealthcare$203M
0.04%
195ANIK
ANIKA THERAPEUTICS INCHealthcare$203M
0.04%
196FORR
FORRESTER RESEARCH INCIndustrials$200M
0.04%
197AMWL
AMERICAN WELL CORPHealthcare$199M
0.04%
198TNXP
TONIX PHARMACEUTICALS HOLDING CORPHealthcare$198M
0.04%
199SRI
STONERIDGE INCConsumer Cyclical$197M
0.04%
200COOK
TRAEGER INCConsumer Cyclical$193M
0.04%
201EAF
GRAFTECH INTERNATIONAL LTDIndustrials$181M
0.04%
202INGN
INOGEN INCHealthcare$178M
0.04%
203KRRO
KORRO BIO INCHealthcare$177M
0.04%
204LEE
LEE ENTERPRISES INCConsumer Cyclical$175M
0.04%
205MRDN
MERIDIAN HOLDINGS INCCommunication Services$171M
0.04%
206CRBP
CORBUS PHARMACEUTICALS HOLDINGS INCHealthcare$167M
0.04%
207KORE
KORE GROUP HOLDINGS INCCommunication Services$163M
0.03%
208OWLT
OWLET INCHealthcare$162M
0.03%
209CHPT
CHARGEPOINT HOLDINGS INCConsumer Cyclical$146M
0.03%
210UNCY
UNICYCIVE THERAPEUTICS INCHealthcare$144M
0.03%
211RRGB
RED ROBIN GOURMET BURGERS INCConsumer Cyclical$130M
0.03%
212FIRY
FIRY INCTechnology$130M
0.03%
213VTVT
VTV THERAPEUTICS INCHealthcare$130M
0.03%
214BOOM
DMC GLOBAL INCEnergy$128M
0.03%
215JYNT
JOINT CORPHealthcare$127M
0.03%
216CUE
CUE BIOPHARMA INCHealthcare$126M
0.03%
217OPRX
OPTIMIZERX CORPHealthcare$126M
0.03%
218VATE
INNOVATE CORPIndustrials$123M
0.03%
219INSG
INSEEGO CORPTechnology$122M
0.03%
220SPRB
SPRUCE BIOSCIENCES INCHealthcare$120M
0.03%
221UFI
UNIFI INCConsumer Cyclical$118M
0.02%
222MED
MEDIFAST INCConsumer Cyclical$114M
0.02%
223TCX
TUCOWS INCTechnology$114M
0.02%
224SCOR
COMSCORE INCCommunication Services$113M
0.02%
225VRCA
VERRICA PHARMACEUTICALS INCHealthcare$96M
0.02%
226CHRN
CHRONOSCALE CORPIndustrials$94M
0.02%
227LIXT
LIXTE BIOTECHNOLOGY HOLDINGS INCHealthcare$91M
0.02%
228RLYB
RALLYBIO CORPHealthcare$87M
0.02%
229INTG
INTERGROUP CORPConsumer Cyclical$84M
0.02%
230WATT
ENERGOUS CORPTechnology$83M
0.02%
231VNCE
VINCE HOLDING CORPConsumer Cyclical$83M
0.02%
232FRMM
FORUM MARKETS INCHealthcare$83M
0.02%
233AUC
ATIF HOLDINGS LTDFinancial Services$82M
0.02%
234BARK
BARK INCConsumer Cyclical$82M
0.02%
235PIII
P3 HEALTH PARTNERS INCHealthcare$78M
0.02%
236SEAT
VIVID SEATS INCCommunication Services$78M
0.02%
237ACET
ADICET BIO INCHealthcare$76M
0.02%
238AIRG
AIRGAIN INCTechnology$76M
0.02%
239ATRA
ATARA BIOTHERAPEUTICS INCHealthcare$76M
0.02%
240BNAI
BRAND ENGAGEMENT NETWORK INCTechnology$76M
0.02%
241CLNN
CLENE INCHealthcare$76M
0.02%
242BODI
BEACHBODY COMPANY INCCommunication Services$75M
0.02%
243RGS
REGIS CORPConsumer Cyclical$74M
0.02%
244LVO
LIVEONE INCCommunication Services$72M
0.02%
245NMAD
NOMAD POWER SOLUTIONS INCHealthcare$72M
0.02%
246SCLX
SCILEX HOLDING COHealthcare$72M
0.02%
247ASPS
ALTISOURCE PORTFOLIO SOLUTIONS SAReal Estate$72M
0.02%
248AGPU
AXE COMPUTE INCHealthcare$72M
0.02%
249LONA
LEONABIO INCHealthcare$68M
0.01%
250NDLS
NOODLES & COConsumer Cyclical$66M
0.01%
251IMA
IMAGENEBIO INCHealthcare$61M
0.01%
252EDSA
EDESA BIOTECH INCHealthcare$59M
0.01%
253SKIL
SKILLSOFT CORPConsumer Defensive$58M
0.01%
254STEM
STEM INCTechnology$56M
0.01%
255TACT
TRANSACT TECHNOLOGIES INCTechnology$54M
0.01%
256MCRB
SERES THERAPEUTICS INCHealthcare$52M
0.01%
257TIL
INSTIL BIO INCHealthcare$50M
0.01%

Full long-leg book as of July 2026 · cap-weighted · total market cap $471.78B. Hypothetical model holdings — not a registered fund’s portfolio.

Sector Breakdown

11 sectors
Healthcare
46.4%
Technology
21.7%
Consumer Cyclical
9.4%
Communication Services
7.6%
Consumer Defensive
7.4%
Industrials
2.7%
Financial Services
2.6%
Basic Materials
1.2%
Real Estate
0.6%
Utilities
0.2%
Energy
0.0%

Portfolio Style

Size × value map of the long-leg book

257 classified
Value
Blend
Growth
Large
Mid
Small
8%2
10%5
21%8
5%16
10%24
16%32
3%56
3%37
1%17

Share of long-leg capital by market cap × book-to-market, using terciles of the 3,283-name universe at July 2026. Rows: Large ≥ $5.2B, Small < $819M. Columns: Value ≥ 0.62, Growth < 0.34 B/M. The dot marks the capital-weighted centroid of the book — 70% toward Large, 64% toward Growth. +23% unclassified (60 missing size/value). Hypothetical holdings — descriptive, not realized P&L.

Tilt over time
Size tilt70% → Large
SmallLarge
Value ↔ growth tilt64% → Growth
ValueGrowth

Capital-weighted centroid of the long leg, December 2002July 2026; the right-hand end is the same value as the box’s dot. 257 names now. Hypothetical holdings — descriptive, not P&L.

Constraint checks

How this book measures against the concentration and liquidity rules — as implemented here

How this book was built

These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.

Passed
4
Failed
1
Not tested
2
Independent checks
7

7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.

2 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.

  • The fund will not concentrate: no more than 25% of total assets in any one industry (excluding government securities and cash items).

    Required
    <= 25.0%
    Actual
    31.3%
    Margin
    -6.3%
Reported separately — arithmetically implied

Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.

No verdict sits within 1.0pp of its limit.

Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700

Measured on the 2026-07 formation date across 257 holdings (cap-weighted). A different formation date can produce different verdicts.

Derivatives risk (Rule 18f-4)

Whether this long-only book is subject to the VaR tests at all

This assessment describes the long-only book this fund holds — the top bucket only.

Governing rule
Rule 18f-4(c)(4) limited derivatives user exception

This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.

Limited derivatives user exceptionby construction

Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.

Qualifies
Required
<= 10% of net assets
Exposure
0% of net assets
Margin
+10pp

No confidence interval: this follows from portfolio construction, not from an estimate.

Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.

Informational — does not govern

This fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.

Measured
1.7 (95% CI 1.0-2.1)
x reference VaR
Limit
2.00x
<= 2.00x reference VaR
Fund VaR
15.6%
99% / 20d
Reference
9.3%
FF5 market (mkt)

historical method · 283 monthly observations · about 2.8 in the 99% tail · paired percentile bootstrap over months

Same test, three estimators
historical
1.68x
within
parametric
1.61x
within
cornish fisher
1.64x
within

The estimators agree, which is mild evidence the number isn’t an artefact of one method.

Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.

The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.

See the long-short verdict on the factor page →

Since publication

Did the edge survive the paper coming out?

published 1985
Entirely since publication
All 283 months of our record post-date the 1985 paper.
Sharpe -0.32-6.2% p.a.January 2003July 2026

There is no “before” to compare against — the predictor was already public when our data begins, so every month shown is out-of-sample relative to the original study.

Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.

Consistency across eras

Is this record broadly durable, or one regime?

22 windows
Positive windows
36%
8 of 22 3-year windows made money
Worst window
-1.50
Sharpe, January 2023 – December 2025
January 2003July 2026
Median Sharpe
-0.28
Dispersion
0.69
Best window
1.04

3-year rolling windows, stepping 1 year (22 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.

Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.

Returns

Long leg is what this fund holds — long-short is shown for reference

since January 2003
Trailing
PeriodLong legLong-short
1 yearcum.18.0%0.6%
3 yearsp.a.1.5%-22.0%
5 yearsp.a.7.5%-10.7%
10 yearsp.a.4.9%-14.9%
Since inceptionp.a.6.9%-7.7%
Calendar years
YearLong legLong-short
20267 mo1.7%-6.4%
20254.8%-19.4%
2024-4.9%-35.7%
202316.7%-28.9%
202217.2%80.5%
202129.1%-2.5%
2020-11.5%-40.3%
20198.5%-20.5%
2018-21.3%-21.4%
20177.4%-19.3%
201626.3%29.9%
2015-22.3%-24.6%
201410.0%3.6%
201343.5%11.8%
201245.7%27.7%
2011-29.3%-32.8%
201019.6%-0.4%
200928.3%-19.2%
2008-24.1%60.3%
20070.0%-27.1%
20067.7%8.9%
20055.4%-3.7%
20046.7%-13.8%
200348.4%-1.1%

Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.

Fund Facts

Ticker (pseudo)FLRR
IssuerETF Foundry Research (hypothetical)
SeriesHypothetical Model Portfolio Series (not a registered trust)
Expense ratio0.29% (placeholder)
Inception2020-07-22 (placeholder)
Listing exchangeNot listed (hypothetical)
CUSIPNot applicable (hypothetical model portfolio)
RebalanceMonthly
Holdings as ofJuly 2026
Total mkt cap (long leg)$471.78B

Methodology

The Foundry Long-Term Reversal Factor ETF tracks a rules-based model that ranks liquid U.S. common stocks (price > $5, market-cap floor) each month by a Long-Term Reversal signal and holds the top decile with the lowest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.

This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.

Documents (draft — hypothetical)

Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.

Summary Prospectus

Objective, fees, strategy, and key risks.

View →
Prospectus

Full strategy, model methodology, and risks.

View →
Statement of Additional Information

Policies, construction, and governance.

View →
Fact Sheet

One-page snapshot with top holdings.

View →
Daily Holdings

Full current constituent list.

View →

DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.